Valneva (NASDAQ:VALN) Trading Up 4.3%

Valneva SE (NASDAQ:VALN - Get Free Report)'s stock price was up 4.3% during trading on Thursday . The company traded as high as $8.83 and last traded at $8.82. Approximately 1,177 shares changed hands during trading, a decline of 87% from the average daily volume of 9,275 shares. The stock had previously closed at $8.46.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on VALN shares. Guggenheim decreased their price target on Valneva from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Friday, March 22nd. HC Wainwright restated a "buy" rating and set a $26.00 price target on shares of Valneva in a research note on Thursday, March 21st.

Valneva Stock Up 5.0 %

The business has a 50-day moving average price of $7.66 and a two-hundred day moving average price of $9.78. The company has a quick ratio of 1.37, a current ratio of 1.65 and a debt-to-equity ratio of 1.04. The firm has a market cap of $617.49 million, a PE ratio of -5.41 and a beta of 2.25.

Institutional Trading of Valneva

Large investors have recently modified their holdings of the stock. Jane Street Group LLC increased its holdings in Valneva by 85.9% in the first quarter. Jane Street Group LLC now owns 16,584 shares of the company's stock valued at $569,000 after buying an additional 7,664 shares during the last quarter. Bank of America Corp DE purchased a new position in shares of Valneva during the first quarter worth about $858,000. Finally, UBS Group AG purchased a new position in shares of Valneva during the second quarter worth about $31,000. Hedge funds and other institutional investors own 11.39% of the company's stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.